The FDA has granted marketing authorization for Zyn nicotine pouches, marking a historic first for the agency in approving such products as less harmful alternatives to traditional cigarettes. This decision follows an extensive scientific review, leading to claims that the pouches could potentially assist adult smokers in reducing or quitting smoking altogether. Despite acknowledging that Zyn is not completely safe, the FDA believes that the public health benefits outweigh the risks associated with its use. The approval has reportedly caused a rise in stock prices for Philip Morris, the company behind Zyn, as they gear up to market this innovative product.